Patents by Inventor Ravi Pratap Narayan Mishra

Ravi Pratap Narayan Mishra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Codon optimized polynucleotide for high level expression of CRM197
    Patent number: 10280409
    Abstract: The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 7, 2019
    Assignee: BIOLOGICAL E LIMITED
    Inventors: Akshay Goel, Ravi Pratap Narayan Mishra, Narender Dev Mantena, Mahima Datla
  • Compositions for immunising against
    Patent number: 10195263
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 5, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20170340720
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 30, 2017
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Fabio BAGNOLI, Massimiliano BIAGINI, Luigi FIASCHI, Guido GRANDI, Ravi Pratap Narayan MISHRA, Nathalie NORAIS, Maria SCARSELLI
  • CODON OPTIMIZED POLYNUCLEOTIDE FOR HIGH LEVEL EXPRESSION OF CRM197
    Publication number: 20170306302
    Abstract: The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 wherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRM197 in Escherichia coli and a method for the isolation and purification thereof.
    Type: Application
    Filed: November 17, 2015
    Publication date: October 26, 2017
    Inventors: Akshay Goel, Ravi Pratap Narayan Mishra, Narender Dev Mantena, Mahima Datla
  • Compositions for immunising against
    Patent number: 9642904
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: May 9, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20160158335
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Application
    Filed: December 7, 2015
    Publication date: June 9, 2016
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Fabio BAGNOLI, Massimiliano BIAGINI, Luigi FIASCHI, Guido GRANDI, Ravi Pratap Narayan MISHRA, Nathalie NORAIS, Maria SCARSELLI
  • Compositions for immunising against
    Patent number: 9205142
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: December 8, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20140178425
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Application
    Filed: February 3, 2014
    Publication date: June 26, 2014
    Applicant: NOVARTIS AG
    Inventors: Fabio BAGNOLI, Massimiliano BIAGINI, Luigi FIASCHI, Guido GRANDI, Ravi Pratap Narayan MISHRA, Nathalie NORAIS, Maria SCARSELLI
  • Compositions for immunising against
    Patent number: 8679505
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: March 25, 2014
    Assignee: Novartis AG
    Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20120107340
    Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Application
    Filed: April 14, 2010
    Publication date: May 3, 2012
    Applicant: NOVARTIS AG
    Inventors: Fabio Bagnoli, Massimilliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
  • COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20120093850
    Abstract: Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having deletions, insertions, and/or mutations, are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
    Type: Application
    Filed: September 15, 2011
    Publication date: April 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Fabio BAGNOLI, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli